key: cord-0884142-7vdboshg
authors: Grau, Santiago; Ferrández, Olivia; Martín-García, Elena; Maldonado, Rafael
title: Reconstituted mRNA Covid-19 vaccines may maintain stability after continuous movement
date: 2021-06-12
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.06.007
sha: 62c8c16964d26b7d43d6a90bb0423ee4b70512f7
doc_id: 884142
cord_uid: 7vdboshg

OBJECTIVES: There is an urgent need to ameliorate the possibilities to transport the reconstituted mRNA vaccines from the centralized preparation centers to the vaccination sites to improve the COVID-19 vaccination campaigns. We have analyzed Pfizer-BioNTech and Moderna vaccine integrity under different movement conditions to provide information that may improve the distribution of vaccines to the target population. METHODS: Syringes of reconstituted Pfizer-BioNTech or Moderna COVID-19 vaccines were prepared in a laminar flow chamber to be subjected to a stability analysis in order to evaluate the impact of movement conditions on mRNA integrity. RNA integrity was checked by the lack of RNA peaks under the original mRNA peak in the electropherogram resulting from potential fragments from RNA degradation. Samples were then exposed for 180 min at room temperature (21±1C°, 55±10% of humidity) under different movement conditions. RESULTS: We report that the integrity of the mRNA of the COVID-19 reconstituted vaccines after continuous moderate movement at room temperature is maintained for at least three hours with values of fluorescence units (FU) under the original mRNA peak of 0.38±0.06 in Pfizer-BioNTech and 0.96±1.18 FU in Moderna, equal to the values obtained without movement (0.36±0.08 FU in Pfizer-BioNTech and 1.12±0.19 FU in Moderna). In contrast, the integrity of these vaccines exposed to repeated Vortex shaking was significantly impaired (p<0.001) with values under the original mRNA peak of 1.34±0.31 FU for the Pfizer-BioNTech and 5.03±1.16 FU for the Moderna samples. CONCLUSIONS: The stability of these reconstituted vaccines here reported may improve the efficiency in the ground transportation and distribution of the vaccines, which may lead to shorter and more homogeneous vaccination in cities and rural areas.

Pfizer-BioNTech and Moderna vaccines are composed of mRNA, and the main difference lies in the lipid nanoparticles that integrate the vaccines to protect the mRNA integrity and facilitate cell entry. Due to this difference, the Pfizer-BioNTech vaccine requires storage in freezers between -90ºC to -60ºC, whereas the Moderna vaccine should be stored between -25ºC to -15ºC [1] . Pfizer-BioNTech vaccine reception in hospitals entails their reconstitution and re-storage at temperatures between 2ºC-8ºC with an expiration of 5 days, while the expiration is only 2h at room temperature.

Moderna vaccine can be stored refrigerated between 2ºC-8ºC for 30 days and between 8ºC-25ºC for up to 12h before use. When the first dose is withdrawn from the vial, both vaccines should be held between 2ºC-25ºC and discarded 6h later.

should not be transported to avoid unnecessary movement that could alter mRNA integrity, which represents a major limitation for the rapid spread of vaccination [1, 2] .

However, no information is currently available about the consequences of movement in the reconstituted vaccines' integrity. We have now analyzed Pfizer-BioNTech and Moderna vaccine integrity under different movement conditions and provide novel information crucial to improve the vaccines' distribution to the target population.

The Hospital del Mar (Barcelona, Spain) acted as a reference hospital and the Pharmacy department as a vaccine distributor. Several vials and syringes of Pfizer-BioNTech COVID-19 and Moderna vaccines were returned to the pharmacy department by the vaccination teams after exceeding the expiration time or potential microbiological contamination, such as vials falling to the ground. We selected for this analysis only the vials and syringes with loss of guarantee of lack of microbiological contamination.

Syringes of reconstituted Pfizer-BioNTech or Moderna COVID-19 vaccines (0.5-2 ml) were prepared in a laminar flow chamber to be subjected to a stability analysis to evaluate the impact of movement conditions on mRNA integrity.

For this purpose, samples were exposed for 180 min at room temperature (21±1C°, 55±10% of humidity) under different conditions. A first group (n=12 from Pfizer-BioNTech and n=17 from Moderna) remained without movement during 180 min to mimic the manufacturer's vaccine conditions use after reconstitution. A second group (n=10 from Pfizer-BioNTech and n=16 from Moderna) was exposed to continuous movement during 180 min in swing shaker (Ovan SW-3DE) at 40rpm with an inclination angle (± 8°) to mimic the movement that may occur in ground transportation under the most unfavorable road conditions. A third group (n=8 from Pfizer-BioNTech and n=14 from Moderna) was exposed to 1 min Vortex (Scientific Industries SI™ Vortex-Genie™ 2) at 3200rpm every 20 min during 180 min, a massive shaking reported to impair RNA integrity [3] . A small amount (2µL) of the fresh samples (n=12 from Pfizer-BioNTech and n=23 from Moderna) was extracted before this period under sterile conditions and immediately analyzed to also compare the integrity of the samples before and after exposure to these conditions. Microfluidic measurements to analyze mRNA integrity were performed using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, USA) with the RNA 6000 Nano LabChip kit and the assay Eukaryote total RNA Nano (Genomics Core Facility, University Pompeu Fabra). Results were generated and analyzed with the Bioanalyzer 2100 Expert Software (Version B.0210.SI764) and manual integration combined with smear analysis was used to define regions following the Bioanalyzer user guide. This technique has been validated for evaluation of RNA integrity with high accuracy and precision [4] , and it is widely used to determine such RNA integrity [5] .

One-way ANOVA (group as between-subjects factor) was used followed by multiplegroup comparisons (Newman Keuls) when the main variable was significant (p<0.05) using the Statistical Package for Social Science program SPSS 20.0. Results are expressed as mean ± SEM. The study achieved a power of 99% with our sample size of 8-23 per group.

Our results revealed a negligible mRNA degradation that was non-significant in the Pfizer-BioNTech and Moderna samples exposed to room temperature for 180 min with 

COVID-19 Vaccines. FDA US Food Drug 2020

COVID-19 Vaccine Storage Handl Guid -Pfizer Handl Guid -Pfizer-BioNTech Mod COVID-19 Vaccines

Messenger RNA (mRNA) nanoparticle tumour vaccination

Method validation of in vitro RNA transcript analysis on the Agilent 2100 Bioanalyzer

Bioanalyzer RNA analysis

We are grateful to the Genomics Core Facility of University Pompeu Fabra for assistance with the mRNA integrity analysis. We thank R. Martín and J. Jancyte for their technical support. Figures with drawings are created with BioRender.com.

The data that support the findings of this study are available from the corresponding author upon reasonable request.J o u r n a l P r e -p r o o f